ArriVent BioPharma, Inc. AVBP Income Statement
| FY'25 | FY'24 | ||
|---|---|---|---|
| $153.35M+94.1% | $79M+21.8% | ||
| $24.18M+58.0% | $15.3M+57.7% | ||
| $177.53M+88.2% | $94.31M+26.4% | ||
| $177.53M+88.2% | $94.31M+26.4% | ||
| -$177.53M-88.2% | -$94.31M-26.4% | ||
| $11.23M-18.8% | $13.82M+163% | ||
| -$166.31M-107% | -$80.49M-16.1% | ||
| -$4.41-71.6% | -$2.57+92.3% | ||
| -$4.41-71.6% | -$2.57+92.3% | ||
| 149.3M+20.8% | 123.6M+1,438% | ||
| 149.3M+20.8% | 123.6M+1,438% | ||
| -$166.08M-106% | -$80.7M-16.4% | ||
| $11.23M-18.8% | $13.82M+163% | ||
| —— | -$211K— | ||
| —— | -$211K— | ||
| -$177.53M-88.2% | -$94.31M-26.4% | ||
| -$180.56M— | —— | ||
| -$180.56M— | —— | ||
| -$177.53M-88.2% | -$94.31M-26.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is ArriVent BioPharma, Inc. profitable?
- ArriVent BioPharma, Inc. is not currently profitable: it reported a net loss of $145.2M over the trailing twelve months.
- What is ArriVent BioPharma, Inc.'s earnings per share?
- ArriVent BioPharma, Inc.'s diluted EPS over the trailing twelve months is $-3.47.
- Where does ArriVent BioPharma, Inc.'s income statement data come from?
- Every line is extracted from ArriVent BioPharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.